Noordzij J P, Khidr A, Evans B A, Desper E, Mittal R K, Reibel J F, Levine P A
Department of Otolaryngology--Head and Neck Surgery, University of Virginia Health System, Charlottesville, Virginia, USA.
Laryngoscope. 2001 Dec;111(12):2147-51. doi: 10.1097/00005537-200112000-00013.
Proton-pump inhibitors are often recommended in the treatment of laryngitis secondary to gastric reflux. Despite prospective treatment studies reporting high efficacy, only one previous report has been placebo-controlled and blinded. The objective of this study was to determine the efficacy of omeprazole in treating proven reflux laryngitis.
Prospective, placebo-controlled, randomized, double-blind clinical trial.
Fifty-three patients with one or more reflux laryngitis symptoms were recruited to undergo 24-hour dual-channel pH probe testing. Thirty patients with more than four episodes of laryngopharyngeal reflux were enrolled. By random assignment, 15 patients received 40 mg omeprazole twice a day and the other 15 received placebo for a period of 2 months. Symptoms (hoarseness, throat pain, lump in throat sensation, throat clearing, cough, excessive phlegm, dysphagia, odynophagia, and heartburn) and endoscopic laryngeal signs (erythema, edema, and mucus accumulation) were recorded initially, at 1 month, and 2 months.
In general, most symptom scores improved over time for both the omeprazole and placebo groups. Hoarseness, when patients begin with low hoarseness symptom scores, and throat clearing improved significantly more in patients on omeprazole than in those on placebo during the 2-month study. Throat pain, lump in throat sensation, excessive phlegm, difficulty swallowing, pain with swallowing, and heartburn showed improvement in both treatment arms, signifying the possibility of a placebo effect. Endoscopic laryngeal signs did not change significantly over the course of the study for either treatment group.
A placebo effect appears to exist in the treatment of reflux laryngitis. However, hoarseness, when initially scored low, and throat clearing resulting from reflux laryngitis are effectively treated by omeprazole.
质子泵抑制剂常用于治疗胃反流继发的喉炎。尽管前瞻性治疗研究报告显示其疗效显著,但此前仅有一篇报告采用了安慰剂对照和盲法。本研究的目的是确定奥美拉唑治疗确诊的反流性喉炎的疗效。
前瞻性、安慰剂对照、随机、双盲临床试验。
招募53例有一项或多项反流性喉炎症状的患者进行24小时双通道pH探头测试。纳入30例有超过4次喉咽反流发作的患者。通过随机分配,15例患者每天服用两次40毫克奥美拉唑,另外15例患者服用安慰剂,为期2个月。最初、1个月和2个月时记录症状(声音嘶哑、咽痛、咽部异物感、清嗓、咳嗽、痰液过多、吞咽困难、吞咽痛和烧心)和喉镜检查体征(红斑、水肿和黏液积聚)。
总体而言,奥美拉唑组和安慰剂组的大多数症状评分随时间改善。在为期2个月的研究中,对于初始声音嘶哑症状评分较低的患者,服用奥美拉唑的患者声音嘶哑和清嗓改善明显优于服用安慰剂的患者。咽痛、咽部异物感、痰液过多、吞咽困难、吞咽痛和烧心在两个治疗组中均有改善,这表明可能存在安慰剂效应。两个治疗组的喉镜检查体征在研究过程中均无显著变化。
反流性喉炎的治疗似乎存在安慰剂效应。然而,对于初始评分较低的声音嘶哑以及反流性喉炎引起的清嗓症状,奥美拉唑治疗有效。